The Study Design and Patient Population

The zorevunersen development program was built to answer two foundational questions in parallel: does the compound do what the mechanism predicts, and can it be administered safely in children with an already complex and treatment-burdened disease? Four studies -- MONARCH and SWALLOWTAIL in the United States, and ADMIRAL and LONGWING in the United Kingdom -- addressed these questions through a combination of single-dose and multi-dose designs, with open-label extension periods that have now extended follow-up to as long as six years for some of the earliest enrolled patients.

Dr. Wheless describes the overall architecture of the program. As with many first-in-human studies, the initial work was designed to evaluate dose ranging, safety, and pharmacokinetics across a phase 1 and 2a framework. Patients in the studies received either single or multiple doses of zorevunersen, followed by standardized maintenance dosing in the open-label extension. Beyond the expected seizure and safety endpoints, the program was designed from the start to capture non-seizure outcomes including communication, socialization, and motor function -- reflecting the recognition that disease modification, if it occurred, would need to be measurable across the full spectrum of Dravet's burden.

Dr. Wirrell addresses the efficacy picture, noting that despite being a secondary outcome in a phase 1/2 framework, the seizure data was striking. Approximately half of enrolled patients were already on fenfluramine, with significant proportions also on cannabidiol and stiripentol -- the most effective available therapies for Dravet. Yet they were still carrying significant seizure burdens and developmental concerns at baseline. Across dose cohorts, seizure reductions of 60 to 90% were observed long term, with the 70 mg dose showing the best outcomes, and those reductions were maintained through 36 months. The Vineland Adaptive Behavior Scales data showed incremental developmental growth at years one, two, and three, in sharp contrast to the trajectories seen in the BUTTERFLY natural history study.

Dr. Schreiber and Dr. Wheless both emphasize the severity of the enrolled population. The eligibility criteria required at least four motor seizures per month, but the average patient was experiencing 17, and more than 80% were taking three or more antiseizure medications simultaneously. This was not the typical Dravet patient -- this was the most treatment-resistant end of the spectrum, and yet the efficacy signal was robust, which both panelists note makes the results even more meaningful for the broader clinical population.

In the next episode, the panelists focus on the seizure outcome data in detail, discussing what the reduction figures mean in clinical terms and why the durability of response -- sustained over years without the honeymoon effect seen with many antiseizure medications -- is one of the most significant features of the zorevunersen data.